Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases

Life Sciences, Pharmaceutical, Drug Discovery & Development, Biomarkers,
  • Wednesday, October 23, 2024 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
  • 60 min

Globally, more than 20 million people are diagnosed with Alzheimer’s disease. Researchers have made tremendous progress in understanding Alzheimer’s disease pathology, resulting in a consensus on the biological definition of the disease. Novel blood-based biomarkers, such as pTau217 and Aβ 42/40, have also emerged.

Now, with the approval of Eisai and Biogen’s LeqembiTM and Lilly’s KisunlaTM, therapeutic development efforts by biopharma have been reinvigorated, and diagnostics are now enabled by available therapies. The shifting dynamics of therapeutic development in dementia and neurodegenerative disease treatment requires an understanding not only of the diseases themselves but also an understanding of the patient care continuum from diagnosis to treatment.

To fully realize the benefits of promising emerging biomarkers like Aβ 42/40 or pTau217, the global ecosystem for bringing these biomarkers into practical use in drug development and diagnostic environments must be considered.

In this webinar, the expert speakers discuss novel biomarkers relevant to Alzheimer’s disease and other neurodegenerative diseases and explore various platforms that support these biomarkers across a range of regulatory environments. They will bring real-life examples featuring innovative solutions and ecosystem partnerships that must be considered with global Alzheimer’s disease clinical trial approaches.

Join this webinar to learn more about how a holistic understanding of the disease pathology of Alzheimer’s disease, Lewy body dementia and more — in both diagnostics and drug development — can drive accelerated therapies to patients in need.

Speakers

Dr. Magali Dupont, Labcorp

Dr. Magali Dupont, Staff Scientist, Immunology, Labcorp

Dr. Magali Dupont holds a PhD in Immunology from the Institut Pasteur in Paris and joined the immunology department at Labcorp Central Laboratory Services in 2021. In her role, she oversees validation work performed at the central laboratory in Geneva, Switzerland, addresses scientific operational challenges and investigates new biomarkers and methodologies to ensure high-quality scientific delivery.

With the increased focus on biomarkers for neurodegenerative diseases, Dr. Dupont has led the validation and operationalization of several assays and platforms to support clinical trials, as well as acquired valuable functional experience, allowing Labcorp to offer multiple approaches to support neurobiomarker testing.

Message Presenter
Robert Martone, Labcorp Drug Development

Dr. Robert Martone, Scientific Discipline Director, Neurology, Labcorp

Dr. Robert Martone is a Research Scientist with deep expertise in neurodegeneration, neuro-oncology, biomarkers and drug discovery. He investigated hereditary neuropathies and the molecular biology of the blood-brain barrier at Columbia University and subsequently managed a portfolio of drug discovery programs at Wyeth Neuroscience targeting Alzheimer’s and Parkinson’s disease.

He served as the Neuroscience Therapeutic Area Lead for the Former Covance Biomarker Center of Excellence. More recently, he served as Director of Pre-Clinical Research at Cognition Therapeutics and later supported late-stage biomarker and diagnostics efforts at Biogen. He is currently the Scientific Discipline Director for Neurology at the Labcorp Biomarker Solution Center.

Message Presenter

Who Should Attend?

This webinar will appeal to those with the following job titles or working in the following fields:

  • Biopharmaceutical Developers
  • Research and Development Directors
  • Clinical Development Leads
  • Biomarker Discovery/Development Scientists
  • Clinical Biomarker Leads
  • Head of Personalized Medicine
  • Translational Biomarker Scientists

What You Will Learn

Attendees will learn about:

  • The rapidly evolving landscape of Alzheimer’s disease therapy development and treatment
  • Key considerations for various platforms and strategies to incorporate biomarkers into their global clinical trials
  • Examples of global clinical trial inclusion of biomarkers of interest
  • How advances in Alzheimer’s disease pathology and progression are being applied to accelerate therapeutic development for other dementias such as Lewy body dementia

Xtalks Partner

Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at https://www.labcorp.com/ or follow us on LinkedIn and Twitter.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account